Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 2Solid Tumor 1Lung Neoplasms 1Hematologic Neoplasms 1Heart Failure 1Cytokine Release Syndrome 1Atrial Fibrillation 1

Interventions

siltuximab 4tocilizumab 3fludarabine 3Cyclophosphamide 3fludarabine phosphate 2Interleukin 1 Receptor Antagonist Protein 2AP 1903 reagent 2talquetamab 1otelixizumab 1obinutuzumab 1lopinavir-ritonavir drug combination 1glofitamab 1axicabtagene ciloleucel 1Piperacillin, Tazobactam Drug Combination 1Oxygen Inhalation Therapy 1Oxaliplatin 1Neuropsychological Tests 1Metoprolol 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Lopinavir 1Leukapheresis 1Infliximab 1Hydroxychloroquine 1Heparin, Low-Molecular-Weight 1Gemcitabine 1Gelsolin 1Etanercept 1Dexamethasone 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cytokine Release Syndrome × Metoprolol × Clear all
NCT04082910 2022-04-13

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Chinese PLA General Hospital

Phase 1/2 Unknown
30 enrolled
Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡